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Background
A four- to seven-fold increase in the prevalence of current mood,
anxiety, substance use and any mental disorders in Indigenous
adults compared with non-Indigenous Australians has been
reported. A lifetime prevalence of major depressive disorder was
23.9%. High rates of comorbid mental disorders indicated a
transdiagnostic approach to treatment might be most appropri-
ate. The effectiveness of psychological treatment for Indigenous
Australians and adjunct Indigenous spiritual and cultural healing
has not previously been evaluated in controlled clinical trials.
Aims
This project aims to develop, deliver and evaluate the
effectiveness of an Indigenous model of mental healthcare
(IMMHC). Trial registration: ANZCTR Registration Number:
ACTRN12618001746224 andWorld Health Organization Universal
Trial Number: U1111-1222-5849.
Method
The IMMHC will be based on transdiagnostic cognitive–behav-
iour therapy co-designed with the Indigenous community to
ensure it is socially and culturally appropriate for Indigenous
Australians. The IMMHC will be evaluated in a randomised con-
trolled trial with 110 Indigenous adults diagnosed with a current
diagnosis of depression. The primary outcome will be the
severity of depression symptoms as determined by changes in
Beck Depression Inventory-II score at 6 months post-interven-
tion. Secondary outcomes include anxiety, substance use
disorder and quality of life. Outcomes will be assessed at base-
line, 6 months post-intervention and 12 months post-
intervention.
Results
The study design adheres to the Consolidated Standards of
Reporting Trials (CONSORT) statement recommendations and
CONSORT extensions for pilot trials. We followed the Standard
Protocol Items for Randomised Trials statement recommenda-
tions in writing the trial protocol.
Conclusions
This study will likely benefit participants, as well as collaborating
Aboriginal Medical Services and health organisations. The
transdiagnostic IMMHC has the potential to have a substantial
impact on health services delivery in the Indigenous health
sector.
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The burden of disease attributable to mental health disparities
account for as much as 16% in Indigenous Australians1 (in this
manuscript, we respectfully refer to Aboriginal and Torres Strait
Islander people as Indigenous Australians), which may be a major
underestimation given accurate data on prevalence of mental disor-
ders in Indigenous Australian have not been available. Our previous
mental health prevalence study found that the prevalence of current
common mental disorders in a cohort of 544 Indigenous
Australians was more than four times that of the general
Australian population, markedly higher than previous estimates.2
Standardised prevalence rates of current, 12-month and lifetime
mood disorders were 16.2% (12.2–20.2%), 19.5% (15.1–23.8%)
and 32.2 (27.1–37.3%), respectively; 6.4, 3.1 and 2.2 times higher,
respectively, than those of the general Australian population.3
Although disproportionate burden of mental disorders among
Indigenous people has been attributed to the intergenerational
impact of colonisation, others have acknowledged that interven-
tions and services currently available may not be effective or cultur-
ally appropriate in supporting the health needs of Indigenous
Australians.4 Despite this notion, and the high levels of poor
mental health,2 the efficacy of treatments has rarely been assessed
in controlled trials.5 An urgent priority exists for the treatment of
mental illness, and specifically depression, in this population.
Major barriers (cultural, economic and geographic) exist to the util-
isation of the limited ambulatory services available. In addition, vir-
tually no robust evidence exists regarding effective and culturally
acceptable treatments for mental disorders in Indigenous people.
Addressing the imbalance
There is now considerable literature available on the importance of
culturally appropriate healthcare6 and guiding principles need to
achieve community acceptance and ‘buy in’ from patients.7
Treatments and services that have been efficacious in other health
conditions, have been those that include Indigenous people in the
design and delivery of the service, and recognise and support cul-
tural concepts of health, social and emotional well-being.8 To facili-
tate an inclusive approach to healthcare development, a desirable
methodology is the application of community-based participatory
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research (CBPR) principles and strategies.9 CBPR is a partnership
approach to research that equitably involves community
members, organisational representatives and researchers in all
aspects of the research process and in which all partners contribute
expertise and share decision-making and ownership.9,10 For
instance, some studies have utilised CBPR principles and strategies
to establish that land, culture, spirituality, ancestry, family and com-
munity are central to the Indigenous Australian understanding of
mental health and therefore central to the design of a mental
health treatment programme.11
For Indigenous Australians, the role of mental health and well-
being revolves around holistic concepts of social and emotional
well-being. The National Aboriginal and Torres Strait Islander
Social Survey (NATSISS).12 identifies these concepts including
those of cultural attachment/participation, identity, language, spir-
ituality, loss and traditional activities. Dockery13 demonstrated the
construct validity of the NATSISS through factor analysis. He also
found strong scores of association and positive responses to ques-
tions investigating levels of happiness and mental health measures
derived from the 36-item Short-Form Health Survey. Positive asso-
ciations of identity and cultural attachment not only associated with
happiness, but quantifiable social measures such as education,
employment and general health.13 Indigenous conceptions of
mental health are deeply rooted in the history of colonisation and
cultural understandings. Further, the intersection of conceptions
of ethnicity and mental illness can be detrimental to the overall
social and emotional well-being of a group.14 Therefore incorporat-
ing social, emotional, spiritual and cultural well-being with psycho-
logical therapies is a necessary way forward to reducing the burden of
mental health issues for Indigenous Australians. Given that depres-
sion is conceptualised within Western epistemology it is argued
that there is no ideal measure of depression within Australian
Indigenous populations.15 Although no specific validation measure
is available, nevertheless, the Beck Depression Inventory (BDI) and
the BDI-II have been used as a measure of depression in studies
with both Australian and Canadian Aboriginal populations.16
Moreover, the BDI-II is specifically designed to be used as an
outcome measure for cognitive–behaviour therapy (CBT) as it dir-
ectly assesses the cognitions of the patient.
Transdiagnostic CBT
Of the psychological therapies, CBT has the strongest evidence base
for treating most mental disorders, especially depression, anxiety
(including post-traumatic stress disorder) and substance use disor-
ders.17 However, CBT could still be further refined to improve out-
comes for patients in the treatment of comorbid mental disorders.17
Transdiagnostic CBT approaches to treatment that cut across diag-
nostic boundaries to target the common cognitive, emotional,
physiological or interpersonal processes that underlie and maintain
mental health symptoms may be most beneficial for individuals
with comorbid disorders.18,19
A recent meta-analysis of transdiagnostic psychological treat-
ments for adult depressive and anxiety disorders found they resulted
in large reductions in anxiety, depression and comorbid depression
and anxiety disorders, as well as moderate improvements in quality
of life that were maintained for 3–6 months after treatment.20
Evidence for transdiagnostic approaches to comorbid substance
use and mental disorders is also emerging.21 Research, however, is
yet to explore the efficacy of either traditional or transdiagnostic
CBT among Indigenous populations. A recent qualitative study sup-
ported the suitability and effectiveness of CBT for Indigenous
peoples.20 Five university-educated Aboriginal counsellors, trained
in CBT for the project, noted the adaptability of the techniques
and reported they were effective in enhancing the well-being of
Aboriginal clients.20 They also highlighted the need for CBT to be
adapted to the social and cultural contexts in which it will be
delivered.20
Aims and objectives
The primary objective will be to determine the effectiveness of the
model of care (Indigenous model of mental healthcare (IMMHC))
in Indigenous participants with depression by measuring differ-
ences between changes in the treatment as usual (TAU) and
IMMHC groups on depression scores as measure by the BDI-II
from baseline to 6 months.
Secondary objectives will include: evaluating the sustainability
of improvements in BDI-II scores over a period of 12 months, mon-
itoring changes in comorbid mental health conditions (any anxiety
disorder and/or substance use disorder) over 12 months, and
changes in quality of life, changes in subsequent healthcare service
use and associated costs, and the effectiveness and appropriateness
of recruitment and study procedures over the 12 months.
Method
Study design
The study is a randomised controlled trial (RCT) of an IMMHC,
based on transdiagnostic CBT and co-designed with the Indigenous
community, to evaluate the effectiveness of the treatment of
depression. Trial registration: ANZCTR Registration Number:
ACTRN12618001746224 and World Health Organization Universal
Trial Number: U1111-1222-5849.
The development of the programme will use CBPR principles22
and involve community members and Elders; psychologists cur-
rently working at the Aboriginal Medical Service (AMS); psycholo-
gists from other medical services; Indigenous mental health
workers; Indigenous peer-support workers; Indigenous spiritual
healers; AMS board members; and current and former patients,
and will be manualised upon development. Additional focus
groups and one-on-one interviews will be conducted during each
phase of the co-design, co-delivery and evaluation of the study.
CBPR principles will ensure that a collaborative approach to the
research protocol is implemented. This will determine appropriate
language and the concepts that are used in the reduction of depres-
sion as described by those participating in the CBPR. It will also
provide important insight into mental health treatment issues and
approaches that need to be considered.
The study design adheres to the Consolidated Standards of
Reporting Trials (CONSORT) statement23 recommendations and
CONSORT extensions for pilot trials.24 We followed the Standard
Protocol Items for Randomised Trials statement recommendations
in writing the trial protocol.25
Randomisation procedure
This will be a randomised controlled parallel group (1:1) trial in
adult Indigenous participants with depressive disorders from par-
ticipating AMSs. Participants will be randomly allocated to
IMMHC or TAU (1:1 ratio) in block sizes of 2, 4, 6, 8 and 10.
Block sizes will be allocated unequally using Pascal’s triangle in
the ratio 1:4:6:4:1. This will reduce any predictability of the random-
isation codes or the blocks. Concealment will be achieved using
opaque envelopes. Those who prepare the randomisation list and/
or the concealed envelopes will not be involved in recruitment or
data collection.
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Setting
Study activities will be conducted at locations associated with AMSs
and other mainstream medical services in Toowoomba and
Warwick (South East Queensland, Australia).
Sample size calculation
The sample size estimates are based on a 2 × 2 repeated measures
design comparing changes in BDI-II scores between the two
groups (IMMHC and TAU). The primary goal of the study is to
compare the change across time in the IMMHC group with the
change across time in the TAU group. Sample sizes of 44 in both
groups achieve 80% power to detect a difference in mean changes
of 6.8 with a standard deviation of 12.8 at the first time point, a
standard deviation of 12.0 at the second time point, and a correl-
ation between measurement pairs of 0.6. The significance level
(alpha) is a P-value of 0.05 using a two-sided, two-sample t-test.
Based on previous research and experience a 20% drop-out rate is
anticipated. Assuming a 20% drop-out rate, the total sample size
required is 110.
Inclusion criteria
(a) 18 years or older and of Aboriginal and/or Torres Strait
Islander descent.
(b) Able to provide written informed consent.
(c) English-language proficiency sufficient to complete study
questionnaires.
(d) A current (30-day) diagnosis of depression (any subtype), with
or without other mood, anxiety or substance use disorders as
diagnosed from a Structured Clinical Interview for DSM-5
Disorders (SCID-5)23 interview.
Exclusion criteria
(a) Cognitive impairment, as determined through the Kimberley
Indigenous Cognitive Assessment (KICA) screening.24
(b) High-risk of suicide, as determined by the SCID-5 clinical
interview, and question nine on the BDI.25
(c) Recent (past 6 weeks) change in psychiatric medication.
(d) Any mental or physical condition requiring hospital
admission.
(e) Diagnosis of organic brain disorder.
(f) Bipolar disorder.
(g) Psychotic disorder.
(h) Another mental disorder (for example likely personality dis-
order based on client self-report) that, in the opinion of a clin-
ical psychologist, is likely to interfere with their ability to
engage in or complete the study.
(i) Another medical condition likely to prevent participation in
the study for 12 months.
Participant recruitment procedure
Participants will be individuals attending participating AMSs and
mainstream medical services in either Toowoomba or Warwick.
Recruitment methods will include: advertising using flyers and
posters, recruitment in the AMS waiting rooms and word of
mouth. If individuals are interested, they will be provided a reply
slip to fill out, via mail or in person, and will be given a participant
information pack. An appointment for the screening interview may
be made at this time if they are agreeable or will be made based on
the suggested time that the participant indicates on the reply slip.
The researchers will meet with the staff member/s prior to recruit-
ment and ensure they understand the RCT sufficiently to provide
the initial introduction to potential participants at the recruitment
stage.
(a) Advertising: posters advertising the project will be displayed in
the participating AMSs andmedical services, and on local com-
munity noticeboards.
(b) Cold calling: a dedicated and trained staff member of the AMS
will contact participants from our previous studies who con-
sented to be re-contacted for future research to discuss the
study. Those interested in finding out more will be posted a
participant information pack.
(c) Waiting room recruitment: a trained staff member will recruit
participants from the waiting area of the AMS or medical
service. The staff will approach potential participants and
provide information about the study.
(d) Word of mouth: past studies with this population have shown
word of mouth to be an effective method of recruitment so this
will be used for the current study.
Study arms
Intervention – IMMHC
This will be documented and delivered by qualified psychologists
trained in the treatment package. The psychologists will receive
weekly cultural and clinical supervision and fidelity will be assessed
by video-taping a random selection of sessions (n = 20) over the
duration of the intervention. These tasks will be performed by the
supervising clinical psychologist. Competence and fidelity to CBT
will be assessed using the Cognitive Therapy Scale – Revised to
rate a random selection of videotaped sessions (n = 20) over the dur-
ation of the entire study. Treatment will consist of both individual
and group psychotherapy, as described below. Individual sessions
will comprise tailored CBT and traditional spiritual healing; group
sessions (co-facilitated with an indigenous health worker) will
focus on skills practice, including yarning (informal conversation)
about successes and difficulties in application, and developing
peer support and reinforcement in this area.
(a) Individual treatment. The first sessionwill involve the assessment
of cognitive and behavioural factorsmaintaining the disorder. As
our previous study2 demonstrated that these assessments are
typically lengthy, the sessions will be up to 90 min. The treating
psychologistwill thendevelop a tailored 6-month treatmentplan,
in consultation with a senior clinical psychologist and the trad-
itional healer, as well as the participant. Changes in symptom-
atology may warrant adjustments or changes to the treatment
plan. A minimum of 10 and up to 12 sessions of individual
treatments will be provided by qualified psychologists using a
combination of face-to-face delivery for primary treatment and
telephone delivery to facilitate skills practice. The duration of
this intervention period will vary for participants, based on
their tailored 6-month treatment plan.
(b) Group treatment. The efficacy of CBT relies on the use of
‘homework’ or skills practice by the patient to maintain treat-
ment effects. Based on our previous research, we believe that
skills practice is likely to be difficult for many Indigenous parti-
cipants, so we will use traditional healing sessions as a way to do
homework. Traditional healers will work with participants to
find out what their homework is and practise this with indivi-
duals. In addition, follow-up calls by the traditional healers
and project team to check on participants and support them
between sessions will be incorporated. Group treatment will
also be provided via a ‘yarning skills group’ as an adjunct to indi-
vidual sessions. The purpose of this group is to build on skills
learned in individual sessions, provide further peer support in
a positive supportive environment, and focus on personal and
group strengths. Group treatment aims to be therapeutic,
strengths-based, and culturally friendly by: using traditional
and spiritual healers, psychologists and Indigenous care
Protocol for transdiagnostic CBT co‐designed with the Indigenous community
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co-coordinators as group facilitators; exploring successes in
applying skills and learnings obtained from individual sessions;
and allowing peers to support each other through learning new
behaviours. Consistent with another evidence-based therapy
that has adapted CBT for complex presentations using both
individual and group CBT; a different psychologist will be
used for individual and group sessions. Participants will be
offered three to five group sessions over a period of 6 months,
with no more than ten participants in each session group.
TAU
All diagnoses arising from the SCID–5 Screening interview will be
entered on patient files and clients’ name provided to the AMS or
medical service for follow-up. Participants who are randomised
into the TAU group will receive the standard treatment offered to
clients with a diagnosed mental illness. This will include a first
appointment with a general practitioner who will then determine
the most appropriate treatment required for the participants. This
may include referral to a psychologist; a mental healthcare plan;
and/or medication.
Post-study treatment for the control group
Should the IMMHC prove more efficacious than TAU, participating
AMSs and/or medical services will adopt it as a standard treatment
option for individuals diagnosed with depression. Following the
intervention study, the 6-month IMMHC intervention will also be
made available to research participants in the control group. It is
the intention of the research team to use psychologists participating
in the study where practicable, including the delivery of the IMMHC.
This should ensure that at least one IMMHC trained psychologist is
available at the participating AMS/medical service to deliver the
model of care post-study. In addition, should the IMMHC prove
more efficacious than TAU, the research team undertakes to
provide a post-study training module to ensure that there are staff
adequately qualified to deliver the IMMHC package into the future.
Interviews
All participants, from both the intervention and TAU groups, will be
invited to attend individual and/or group interviews at the conclusion
of the trial, after the follow-up assessments post-intervention have
been completed, to discuss the reasons why participants may or
may not engage with the study or choose to drop-out. Interviews
will be audio-recorded for subsequent qualitative analyses.
Outcome measures
Primary outcome measure
The difference between changes in the TAU and IMMHC groups on
depression scores as measured by the BDI-II from baseline to 6
months.
Secondary outcome measures
(a) The difference in change of scores as measured by BDI-II from
baseline to 12 months, between the TAU and IMMHC group.
(b) Comparison of changes in quality of life measured using the
Assessment of Quality of Life (AQoL)-8D.26
(i) Changes in quality of life between baseline and 6
months; other changes between baseline and 12 months.
(c) Other changes in mental health.
(i) Anxiety: changes in Beck Anxiety Index (BAI27) – base-
line to 6 months and baseline to 12 months.
(ii) Substance use: changes in scores based on the Alcohol,
Smoking and Substance Involvement Screening Test
(ASSIST).28
(iii) Changes in the presence of major depression, anxiety or
substance use disorder(s), as established by a SCID-5-
Clinician Version (SCID-5-CV) interview at 12 months.
(d) Changes in number of mental health diagnoses and patterns of
psychotropic medication use.
(i) Diagnostic status of initial mental health conditions will
be evaluated using SCID-5-CV at 6 months and 12
months.
(ii) Medications (class, dosage and frequency) will be cap-
tured for both the groups and compared.
(e) Thematic analysis to explore reasons why participants may or
may not engage with the study or choose to drop-out.
Data analysis
Data will be gathered at the point of initial screening for eligibility,
baseline, 6- and 12-month post baseline follow-ups, and at the focus
groups and interviews. See the schedule of assessments in Appendix 1.
Quantitative analysis
Intention-to-treat principles will be used for all analyses.
Differences in mean change in BDI-II scores from baseline to
6 months between the two groups will be analysed using repeated
measures ANOVA, with treatment as the between-subjects factor,
and time as within-subjects factor, and an interaction term (time
and treatment group). Additional analyses will use mixed models
adjusting for baseline covariates including quality of life. We will
also calculate the differences between the groups using hierarchical
mixedmodels for continuous variables (BDI-II and BAI scores mea-
sured at three time points – baseline, 6 months post-intervention
and 12 months post-intervention) containing random intercept
and random slope as well as fixed effects for treatment. We will
also evaluate changes in diagnostic status using logistic and/or
Poisson regression models.
Qualitative analysis
Thematic analysis29 using NVivo will be undertaken to identify
recurring themes in the interview transcripts, and guide interpret-
ation and representation of the information collected. The emerging
themes will guide identification, analysis, organisation and descrip-
tion of the IMMHC intervention. A professional transcription
service will be engaged for the transcription of the interviews.
Ethics approval
The authors assert that all procedures contributing to this work will
comply with the ethical standards of the relevant national and institu-
tional committees on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2008. All procedures involving
human patients were approved by the University of Queensland
Human Research Ethics Committee approved the study (Clearance
No: 2017001872) as well as the Board of Directors of the AMS. The
study will be conducted according to National Health and Medical
Research Council of Australia guidelines and the Ethical Conduct in
Research with Aboriginal and Torres Strait Islander Peoples and
Communities: Guidelines for Researchers and Stakeholders.30
Strengths and limitations
For most patients, psychology-based therapy is more feasible than
treatment by psychiatrist because of the chronic severe shortage
of the latter in Indigenous areas. Additionally, Indigenous mental
health workers, nurses and general practitioners trained in basic
CBT can contribute to its delivery. Multistage evaluation will
provide useful information for the planning and implementation
of other Indigenous health interventions. Development of a
Toombs et al
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community-designed treatment model will promote its effective
national- and international-level implementation to sustain integra-
tion of translational outcomes.
Results
The study design adheres to the Consolidated Standards of
Reporting Trials (CONSORT) statement31 recommendations and
CONSORT extensions for pilot trials.32 We followed the Standard
Protocol Items for Randomised Trials statement recommendations
in writing the trial protocol.33 See Fig. 1 for the study flow chart.
Discussion
Mental illness is a major contributor to the Indigenous health and
mortality gaps. Rectifying the adverse effects of over 200 years of
colonisation by addressing the social determinants underlying this
burden will be slow. In the meantime, an urgent priority exits
among the population for treatment of their mental illnesses. In
addition, virtually no robust evidence exists regarding efficacious
and culturally acceptable treatments for mood, anxiety and sub-
stance use disorders in Indigenous Australians.
This project will address an issue of great importance to the
health of Indigenous Australians. The development of an innova-
tive, effective and sustainable treatment programme that is
endorsed by the community will result in a highly significant
advance in knowledge in this field and major health gains that
will translate to significant changes in policy and practice.
Community ‘buy in’ is an essential component to Indigenous
health interventions and this project is the product of a decade of
robust and meaningful community engagement. This study will
be the first known controlled trial to develop an IMMHC, which
assimilates both Indigenous spiritual and cultural knowledge with
contemporary psychological therapies, such as CBT. This will be
based on CBT, incorporating cultural and narrative elements and
the concepts of social and emotional well-being.
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Allocation to intervention – Indigenous
Model of Mental Healthcare (n = 55)
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Fig. 1 Study flow chart for the Indigenous model of mental healthcare versus treatment as usual for participants with a current 30-day
diagnosis of depression.
RCT, randomised control trial; AMS, Aboriginal Medical Service.
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